[HTML][HTML] Clinical development of new drug–radiotherapy combinations
…, D Sebag-Montefiore, M Smitt, J Staffurth… - Nature reviews Clinical …, 2016 - nature.com
In countries with the best cancer outcomes, approximately 60% of patients receive
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …
A review of the clinical evidence for intensity-modulated radiotherapy
J Staffurth - Clinical oncology, 2010 - Elsevier
AIMS: Intensity-modulated radiotherapy (IMRT) is a development of three-dimensional
conformal radiotherapy that offers improvements in dosimetry in many clinical scenarios …
conformal radiotherapy that offers improvements in dosimetry in many clinical scenarios …
[HTML][HTML] A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration …
…, L Franzèn, P Olivier, A Pecking, J Staffurth… - European journal of …, 2012 - Elsevier
PURPOSE: To investigate the dose–response relationship and pain-relieving effect of
radium-223, a highly bone-targeted alpha-pharmaceutical. METHODS: One hundred …
radium-223, a highly bone-targeted alpha-pharmaceutical. METHODS: One hundred …
[HTML][HTML] Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina… - … England Journal of …, 2011 - Mass Medical Soc
Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor …
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor …
[HTML][HTML] 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer
…, J Oxley, M Robinson, J Staffurth… - … England Journal of …, 2016 - Mass Medical Soc
Background The comparative effectiveness of treatments for prostate cancer that is detected
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …
[HTML][HTML] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
…, AJ Robinson, N Srihari, R Srinivasan, J Staffurth… - The Lancet, 2016 - thelancet.com
Background Long-term hormone therapy has been the standard of care for advanced
prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a …
prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a …
[HTML][HTML] Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
…, J Oxley, NJ Williams, J Staffurth… - … England Journal of …, 2023 - Mass Medical Soc
Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind …
K Fizazi, HI Scher, A Molina, CJ Logothetis… - The lancet …, 2012 - thelancet.com
Background Abiraterone acetate improved overall survival in metastatic castration-resistant
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo …
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo …
[HTML][HTML] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
…, C Parker, H Patterson, C Scrase, J Staffurth… - The Lancet …, 2016 - thelancet.com
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[HTML][HTML] Rucaparib or physician's choice in metastatic prostate cancer
…, H Lindberg, D Morris, F Nolè, J Staffurth… - … England Journal of …, 2023 - Mass Medical Soc
Background In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase
(PARP), showed a high level of activity in patients who had metastatic, castration-resistant …
(PARP), showed a high level of activity in patients who had metastatic, castration-resistant …